MRSA infections in NHS on the rise again in 2016 – while MSSA infections top 10,000 and remain unchecked

23 August 2016

In our weekly expert view piece, Dr Bill Love, chief executive of Destiny Pharma, looks at worrying rises in Methicillin Resistant Staphylococcus aureus (MRSA) and Methicillin Sensitive Staphylococcus aureus (MSSA), in the UK's National Health Service (NHS).

The latest figures for MRSA bacterial blood infections, published on July 7 by Public Health England (PHE) and covering infection in NHS England, have shown a worrying rise with some 819 infections reported in the year 2015/2016, representing a 2.4% increase over last year.

At the same time, the less reported, but more common and life-threatening MSSA bacterial blood infection rate has continued to be ignored and has been allowed to progressively escalate.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK